Progress in the development of neurokinin 3 modulators for the treatment of schizophrenia: Molecule development and clinical progress

Future Medicinal Chemistry

Volumn 5, Issue 13, 2013, Pages 1525-1546

  Dawson, Lee A ^a   Porter, Roderick A ^b  

^a EISAI CO LTD   (Japan)

^b Rod Porter Consultancy Ashwell   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 2624; CYCLOHEXANE DERIVATIVE; GSK 172981; GSK 256471; N (ALPHA ETHYLBENZYL) 3 METHYL 2 PHENYL 4 QUINOLINECARBOXAMIDE; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR ANTAGONIST; OSANETANT; PIPERIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; SAREDUTANT; SB 235375; SULFONE; SULFOXIDE; TALNETANT; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; BRAIN CORTEX; CRYSTALLOGRAPHY; DRUG BRAIN LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; MENTAL PATIENT; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SITE DIRECTED MUTAGENESIS;

ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, NEUROKININ-3; SCHIZOPHRENIA;

EID: 84884233000     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.122     Document Type: Review

References (91)

1. Alvaro G, Di Fabio R. Neurokinin 1 receptor antagonists - current prospects. Curr. Opin. Drug Discov. Devel. 10(5), 613-621 (.2007
2. Ebner K, Sartori SB, Singewald N. Tachykinin receptors as therapeutic targets in stress-related disorders. Curr. Pharm. Des. 15(14), 1647-1674 (.2009
3. Lecci A, Altamura M, Capriati A, Maggi CA. Tachykinin receptors and gastrointestinal motility: Focus on humans. Eur. Rev. Med. Pharmacol. Sci. 12(5 Suppl. 1), 69-80 (.2008
4. Meltzer HY, Prus A. NK3 receptor antagonists for the treatment of schizophrenia. Drug Discov. Today Therap. Strat. 3(4), 555-560 (.2006
5. Smith PW, Dawson LA. Neurokinin 3 (.NK3) receptor modulators for the treatment of psychiatric disorders. In: Frontiers in CNS Drug Discovery; Iqbal-Choudhary M, Rahman A-u (.Eds). Bentham Science, 2, 430-455 (.2010
6. Dawson LA, Smith PW, Watson JM. Will modulation of neuropeptide receptors produce the next generation of antipsychotic drugs? A focus on the neurokinin and neurotensin systems. In: Advances in Pharmacologic Treatments for Schizophrenia. 1st Ed. Wood MW, Albert JS (.Eds). Wiley Press, 381-424 (.2012
7. Mileusnic D, Lee JM, Magnuson DJ et al. Neurokinin-3 receptor distribution in rat and human brain: An immunohistochemical study. Neuroscience 89(4), 1269-1290 (.1999
8. Langlois X, Wintmolders C, te Riele P, Leyson JE, Jurzak M. Detailed distribution of Neurokinin 3 receptors in the rat, guinea pig and gerbil brain: A comparative autoradiography study. Neuropharmacology 40(2), 242-253 (.2001
9. Mussap CJ, Geraghty DP, Burcher E. Tachykinin receptors: A radioligand binding perspective. J. Neurochem. 60(6), 1987-2009 (.1993
10. Rigby M, O'Donnell R, Rupniak NM. Species differences in tachykinin receptor distribution: Further evidence that the substance P (.NK1) receptor predominates in human brain. J. Comp. Neurol. 490(4), 335-353 (.2005
11. Tooney PA, Au GG, Chahl LA. Tachykinin NK1 and NK3 receptors in the prefrontal cortex of the human brain. Clin. Exp. Pharm. Phys. 27(11), 947-949 (.2000
12. Koutcherov Y, Ashwell KW, Paxinos G. The distribution of the neurokinin B receptor in the human and rat hypothalamus. Neuroreport 11(14), 3127-3131 (.2000
13. Whitty C.J, Paul MA, Bannon MJ. Neurokinin receptor mRNA localisation in human midbrain dopamine neurons. J. Comp. Neurol. 382(3), 394-400 (.1997
14. Maggi CA. The mammalian tachykinin receptors. Gen. Pharmacol. 26(5), 911-944 (.1995
15. Dawson LA, Dada S, Langmead CJ et al. In vitro and in vivo comparison of two non-peptide NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. Eur. J. Pharmacol. 627(1/3), 106-114 (.2010
16. Bissantz C, Bohnert C, Hoffmann T, Marcuz A, Schnider P, Malherbe P. Identification of a crucial amino acid in the helix position 6.51 of human tachykinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK1/NK3 antagonists. J. Med. Chem. 55(11), 5061-5076 (.2012
17. Ganjiwale AD, Rao GS, Cowsik SM. Molecular modeling of neurokinin B and tachykinin NK3 receptor complex. J. Chem. Inf. Model. 51(11), 2932-2938 (.2011
18. Jung M, Michaud JC, Steinberg R et al. Electrophysiological, behavioural and biochemical evidence for activation of brain noradrenergic systems following neurokinin NK3 receptor stimulation. Neuroscience 74(2), 403-414 (.1996
19. Nalivaiko E, Michaud J-C, Soubrie P, Le Fur G, Feltz P. Tachykinin neurokinin1 and neurokinin3 receptor mediated responses in guinea pig substantia nigra: In vitro electrophysiological study. Neuroscience 78(3), 745-757 (.1997
20. Marco N, Thirion A, Mons G et al. Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: An in vivo microdialysis approach in guinea pig. Neuropeptide 32(5), 481-488 (.1998
21. Alonso R, Fournier M, Carayon P, Petitpretre G, Le Fur, G, Soubrie P. Evidence for the modulation of dopamine-neuronal function by tachykinin NK3 receptor stimulation in gerbils. Eur. J. Neurosci. 8(4), 801-808 (.1996
22. Bert L, Rodier D, Bougault I et al. Permissive role of Neurokinin NK3 receptors in NK1 receptor-mediated activation of the locus coeruleus revealed by SR142801. Synapse 43(1), 62-69 (.2002
23. Gueudet C, Santucci V, Soubrie P, Le Fur G. Blockade of neurokinin3 receptors antagonizes drug-induced population response and depolarization block of midbrain dopamine neurons in guinea pigs. Synapse 33(1) 71-79 (.1999
24. Dawson LA, Cato KJ, Scott C et al. In vitro and in vivo characterisation of the non-peptide NK3 receptor antagonist SB-223412 (.talnetant): Potential therapeutic utility in the treatment of schizophrenia. Neuropsychopharmacology 33(7), 1642-1652 (.2008
25. Preston Z, Richardson PJ, Pinnock RD, Lee K. NK3 receptors are expressed on mouse striatal gamma-aminobutyric acid-ergic interneurones and evoke [3H] gamma-aminobutyric acid release. Neurosci. Lett. 284(1/2), 89-92 (.2000
26. Furuta T, Koyano K, Tomioka R, Yanagawa Y, Kaneko T. GABAergic basal forebrain neurons that express receptor for neurokinin B and send axons to the cerebral cortex. J. Comp. Neurol. 473(1), 43-58 (.2004
27. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6(4), 312-324 (.2005
28. Stacy AE, Woodhall GL, Jones RS. Neurokinin-receptor-mediated depolarization of cortical neurones elicits increase in glutamate release at excitatory synapses. Eur. J. Neurosci. 16(10), 1896-1906 (.2002
29. Rekling JC. NK-3 receptor activation depolarizes and induces an after-depolarization in pyramidal neurons in gerbil cingulate cortex. Brain Res. Bull. 63(2), 85-90 (.2004
30. Simmons MA, Sobotka-Briner C, Medd AM. Localization and function of NK3 receptors of layer V pyramidal neurons of the guinea pig medial prefrontal cortex. Neuroscience 156(4), 987-994 (.2008
31. Siuciak JA, McCarthy SA, Martin AN et al. Disruption of the neurokinin-3 receptor (.NK3) in mice leads to cognitive deficits. Psychopharmacology 194(2), 185-195, (.2007
32. Nordquist RE, Delenclos M, Ballard TM et al Cognitive performance in neurokinin 3 receptor knockout mice. Psychopharmacology 198(2), 211-220 (.2008
33. Nordquist RE, Savignac H, Pauly-Evers M et al. Characterization of behavioral response to amphetamine, tyrosine hydroxylase levels, and dopamine receptor levels in neurokinin 3 receptor knockout mice. Behav. Pharmacol. 19(5-6), 518-529 (.2008
34. Emonds-Alt X, Bichon D, Ducoux JP et al. SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor. Life Sci. 56(1), PL27-PL32 (.1995
35. Jocham G, Lezoch K, Müller CP, Kart-Teke E, Huston JP, de Souza Silva MA. Neurokinin receptor antagonism attenuates cocaine's behavioural activating effects yet potentiates its dopamine-enhancing action in the nucleus accumbens core. Eur. J. Neurosci. 24(6), 1721-1732 (.2006
36. De Souza Silva MA, Mello EL Jr, Müller CP et al. The tachykinin NK3 receptor antagonist SR142801 blocks the behavioral effects of cocaine in marmoset monkeys. Eur. J. Pharmacol. 536(3), 269-278 (.2006
37. Man J, Jurzak, M, Stohr, T. The NK3 receptor antagonist SR142801 reverses apomorphine-induced deficits on prepulse inhibition in gerbils. Behaviour. Pharmacol. 11(3-4), 343 (.2000
38. Pouzet B, Moller Nielson NS. Preclinical investigation of the antipsychotic-like effect of NK3 receptor antagonists versus marketed antipsychotics in gerbils. J. Psychopharmacol. (.S)17(1), A46 (.2003
39. Salome N, Stemmelin J, Cohen C, Griebel G. Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils. Pharmacol. Biochem. Behav. 83(4), 533-539, (.2006
40. Dableh LJ, Yashpal K, Rochford J, Henry JL. Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur. J. Pharmacol. 507(1/3), 99-105 (.2005
41. Ribeiro SJ, Teixeira RM, Calixto JB, De Lima TC. Tachykinin NK(3)receptor involvement in anxiety. Neuropeptides 33(2), 181-188 (.1999
42. Rance NE, Krajewski SJ, Smith MA, Cholanian M, Dacks PA. Neurokinin B and the hypothalamic regulation of reproduction. Brain Res. 1364, 116-128 (.2010
43. Topaloglu AK, Reimann F, Guclu M, et al TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for neurokinin B in the central control of reproduction. Nat. Genet. 41(3), 354-358, (.2009
44. Noritake K, Matsuoka T, Ohsawa T et al. Involvement of neurokinin receptors in the control of pulsatile luteinizing hormone secretion in rats. J. Reprod. Dev. 57(3), 409-415, (.2011
45. Smith PW, Dawson LA. Neurokinin 3 (.NK3) receptor modulators for the treatment of psychiatric disorders. Recent Patent CNS Drug Disc. 3(1), 1-15 (.2008
46. Malherbe P, Ballard TM, Ratni H. Tachykinin neurokinin 3 receptor antagonists: A patent review (.2005-2010) Expert Opin. Ther. Patents 21(5), 637-655 2011
47. Sarau HM, Griswold DE, Potts W et al. Nonpeptide tachykinin receptor antagonists. I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J. Pharmacol. Expt. Ther. 281(3), 1303-1311 (.1997
48. Simpson TR, Gadient R, Li Y et al. Discovery of AZD2624: A potent and selective NK3 antagonist to test the NK3 hypothesis in schizophrenia. Presented at: 239th ACS National Meeting. San Francisco, CA, USA, 21-25 March 2010
49. Sarau HM, Griswold DE, Bush B et al. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist antagonist. J. Pharmacol. Expt. Ther. 295(1), 373-381 (.2000
50. Hay DWP, Giardina GAM, Griswold DE et al. Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs. J. Pharmacol. Expt. Ther. 300(1), 314-323 (.2002
51. Smith PW, Wyman PA, Lovell P et al. New quinoline NK3 receptor antagonists with CNS activity Bioorg. Med. Chem. Lett. 19(3), 837-840 (.2009
52. Li Y, Zhou D, Ferguson SS, Dorff P et al. In vitro assessment of metabolic drug-drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies. Xenobiotica 40(11), 721-729 (.2010
53. Xiong H, Kang J, Woods JM et al. Synthesis and SAR of sulfoxide substituted carboxyquinolines as NK3 receptor antagonists. Bioorg. Med. Chem. Lett. 21(6), 1896-1899 (.2011
54. Giardina G, Grugni M, Raveglia LF. Recent advances in neurokinin-3 receptor antagonists. Expert Opin. Ther. Patents 10(6), 939-960 (.2000
55. Elliott JM, Carling RW, Chicchi GG et al. Ń,2-Diphenylquinoline-4- carbohydrazide based NK3 receptor antagonists. Bioorg. Med. Chem. Lett. 15(22), 5752-5756 (.2006
56. Elliott, JM, Carling RW, Chambers M et al. Ń,2-Diphenylquinoline- 4-carbohydrazide based NK3 receptor antagonists. Bioorg. Med. Chem. Lett. 15(22), 5748-5751 (.2006
57. Hoveyda HR, Roy M-R, Blanc S et al. Discovery of 3-aryl-5- acylpiperazinylpyrazoles as antagonists to the NK3 receptor. Bioorg. Med. Chem. Lett. 21(7), 1991-1996 (.2011
58. Juhl K, Hansen T, Kehler J et al. Identification of a new series of non-peptidic NK3 receptor antagonists. Bioorg. Med. Chem. Lett. 21(5), 1498-1501 (.2011
59. Ratni H, Ballard TM, Bissantz C et al. Rational design of novel pyrrolidine derivatives as orally active neurokinin-3 receptor antagonists. Bioorg. Med. Chem. Lett. 20(22), 6735-6739 (.2010
60. Meltzer HY, Arvanitis L, Bauer D, Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry. 161(6), 975-984 (.2004
61. Kramer MS, Cutler N, Feighner J et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281(5383), 1640-1645 (.1998
62. Kramer MS, Winokur A, Kelsey J et al. Demonstration of the efficacy and safety of a novel substance P (.NK1) receptor antagonist in major depression. Neuropsychopharmacology 29(2), 385-392 (.2004
63. Keller M, Montgomery S, Ball W et al. Lack of efficacy of the substance P (.neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry 59(3), 216-223 (.2006
64. Peters JU, Hoffmann T, Schnider P et al. Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligands. Bioorg. Med. Chem. Lett. 20(11), 3405-3408 (.2010
65. Malherbe P, Knoflach F, Hernandez MC et al. Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK1 and NK3 receptors. Br. J. Pharmacol. 162(4), 929-946 (.2011
66. Malherbe P, Knoflach F, Steward L et al. Characterization of RO4583298 as a highly potent dual antagonist with in vivo activity at Tachykinin NK1 and NK3 receptors. Schizophr. Res. 117(2/3) 485-486 (.2010
67. Catalani MP, Alvaro G, Bernasconi G et al. Identification of novel NK1/NK3 dual antagonists for the potential treatment of schizophrenia. Bioorg. Med. Chem. Lett. 21(22), 6899-6904 (.2011
68. Te Beek ET, Hay JL, Bullman JN et al. Pharmacokinetics and central nervous system effects of the novel dual NK(1) /NK(3) receptor antagonist GSK1144814 in alcohol-intoxicated volunteers. Br. J. Clin Pharmacol. 75(5). 1328-1339 (.2013
69. Blaney FE, Raveglia LF, Artico M et al. Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists. J. Med. Chem. 44(11), 1675-1689 (.2001
70. Nishi T, Ishibashi K, Takemoto T et al. Combined tachykinin receptor antagonists: Synthesis and stereochemical structure activityrelationships of novel morpholine analogues. Bioorg. Med. Chem. Lett. 10(15), 1665-1668 (.2000
71. Anthes JC, Chapman RW, Richard C et al SCH206272: A potent orally active tachykinin NK(1), NK(2) and NK(3) receptor antagonist. Eur. J. Pharmacol. 450(2), 191-202 (.2002
72. Tsuchida H, Takahashi S, Nosaka E et al. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses. Eur. J. Pharmacol. 586(1-3), 306-312, (.2008
73. Geldenhuys WJ, Kuzenko SR, Simmons MA. Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor. J. Med. Chem. 53(22), 8080-8088 (.2010
74. Malherbe P. Bissantz C. Marcuz A et al. Me-talnetant and osanetant interact with overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domains. Mol. Pharmacol. 73(6), 1736-1750 (.2008
75. Malherbe P, Bissantz C, Knoflach F et al. Mapping the binding site for tachykinin NK3 receptor antagonists schizophrenia research. Schizophr. Res. 102(1-3, Suppl. 2), 65 (.2008
76. Wu LH, Vartanian MA, Oxender DL, Chung FZ Identification of methionine134 and alanine146 in the second transmembrane segment of the human tachykinin NK3 receptor as residues involved in species-selective binding to SR 48968. Biochem. Biophys. Res. Commun. 198(3), 961-966. (.1994
77. Cherezov V, Rosenbaum DM, Hanson MA et al. High-resolution crystal structure of an engineered human b2-adrenergic G protein-coupled receptor. Science 318(5854), 1258-1265 (.2007
78. White JF, Noinaj N, Shibata Y et al. Structure of the agonist bound neurotensin receptor. Nature 490(7421), 508-513 (.2012
79. Wu, B, Chien EYT, Mol CD et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330(6007), 1066-1071 (.2010
80. Granier, S, Manglik A, Kruse AC, Kobilka TS, Thian FS. Structure of the d-opioid receptor bound to naltrindole. Nature 485(7398), 400-404 (.2012
81. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM. Molecular signatures of G-protein-coupled receptors. Nature 494(7436), 185-194 (.2013
82. Malherbe P, Kratzeisen C, Marcuz A et al. Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (.SR 142801) and piperidine-based structures. J. Med. Chem. 52(22), 7103-7112 (.2009
83. Kronenberg G, Berger P, Tauber RF, Bandelow B, Henkel V, Heuser I. Randomized, double-blind study of SR142801 (.Osanetant). A novel neurokinin-3 (.NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (.CCK-4) challenges. Pharmacopsychiatry 38(1), 24-29 (.2005
84. Mesnage V, Houeto JL, Bonnet AM et al. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin. Neuropharmacol. 27(3), 108-110 (.2004
85. Liem-Moolenaar M, Gray F, de Visser S et al. Psychomotor and cognitive effects of a single oral dose of talnetant (.SB-223412) in healthy volunteers compared with placebo or haloperidol. J. Psychopharmacol. 24(1), 73-82 (.2010
86. Evangelista S. Talnetant GlaxoSmithKline. Curr. Opin. Investig. Drugs 6, 717-721 (.2005
87. Bennacef I, Perrio C, Lasne MC, Barre L Functionalization through lithiation of (.S)- N-(1-phenylpropyl)-2-phenylquinoline-4- carboxamide J. Org. Chem. 72(6), 2161-2165 (.2007
88. Bergstrom M, Fasth K-J, Kilpatrick G et al. Brain uptake and receptor binding of two labelled selective high affinity NK-1 antagonists, GR-203040 and GR-205171 - PET studies in rhesus monkeys. Neuropharmacology 39(4), 664-670 (.2000
89. Griebel G, Beeské S. Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases? Pharmacol. Ther. 133(1), 116-123 (.2012
90. de la Flor R, Dawson LA. Augmentation of antipsychotic - induced neurochemical changes by the NK3 receptor antagonist talnetant (.SB-223412), Neuropharmacology 56(2), 342-349 (.2009
91. Ballosteros JA, Weinstein H. Integrated methods for construction of three dimensional models and computational probing of structure function relations in G-protein coupled receptors. Methods Neurosci. 25, 366-428 (.1995